NASDAQ : REPL
Replimune Group, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 17.61 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.67B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 81.48M | 99.62M | 73.06M | 60.72M | 50.97M | 39.18M |
| Research & Development | 186.91M | 218.69M | 186.80M | 172.13M | 123.19M | 75.97M |
| Operating Expenses | 268.39M | 318.31M | 259.85M | 232.85M | 174.17M | 115.14M |
| Operating Income | -268.39M | -318.31M | -259.85M | -232.85M | -174.17M | -115.14M |
| Interest Expense | -10.97M | -8.86M | -7.89M | -6.66M | -4.16M | -2.22M |
| Interest & Investment Income | 9.05M | 13.62M | 21.12M | 23.36M | 10.01M | 390.00K |
| Currency Exchange Gain (Loss) | -37.00K | 300.00K | 200.00K | -800.00K | -5.68M | -1.10M |
| Other Non Operating Income (Expenses) | -1.24M | -1.24M | -402.00K | 1.57M | 41.00K | |
| EBT Excluding Unusual Items | -271.58M | -314.49M | -246.83M | -215.39M | -174.00M | -118.04M |
| Pretax Income | -271.58M | -314.49M | -246.83M | -215.39M | -174.00M | -118.04M |
| Income Tax Expense | -551.00K | -551.00K | 468.00K | 408.00K | 288.00K | |
| Net Income | -271.03M | -313.94M | -247.30M | -215.79M | -174.28M | -118.04M |
| Net Income to Common | -271.03M | -313.94M | -247.30M | -215.79M | -174.28M | -118.04M |
| Shares Outstanding (Basic) | 97.47M | 92.80M | 80.56M | 66.57M | 58.21M | 52.21M |
| Shares Outstanding (Diluted) | 97.47M | 92.80M | 80.56M | 66.57M | 58.21M | 52.21M |
| EPS (Basic) | -2.78 | -3.38 | -3.07 | -3.24 | -2.99 | -2.26 |
| EPS (Diluted) | -2.78 | -3.38 | -3.07 | -3.24 | -2.99 | -2.26 |
| Free Cash Flow | -245.77M | -284.57M | -198.94M | -191.13M | -130.32M | -84.52M |
| Free Cash Flow Per Share | -2.52 | -3.07 | -2.47 | -2.87 | -2.24 | -1.62 |
| EBITDA | -262.64M | -312.56M | -253.92M | -227.77M | -171.72M | -113.00M |
| D&A For EBITDA | 5.75M | 5.76M | 5.93M | 5.08M | 2.45M | 2.15M |
| EBIT | -268.39M | -318.31M | -259.85M | -232.85M | -174.17M | -115.14M |
Balance sheet
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 307.83M | 209.02M | 111.12M | 74.46M | 146.59M | 105.95M |
| Short-Term Investments | 59.87M | 372.69M | 346.21M | 436.80M | 289.71M | |
| Cash & Short-Term Investments | 307.83M | 268.89M | 483.80M | 420.67M | 583.39M | 395.65M |
| Other Receivables | 1.62M | 3.73M | 4.92M | 2.94M | 5.05M | |
| Receivables | 1.62M | 3.73M | 4.92M | 2.94M | 5.05M | |
| Prepaid Expenses | 6.33M | 8.61M | 8.35M | 8.08M | 6.28M | 3.27M |
| Total Current Assets | 324.04M | 279.12M | 495.88M | 433.67M | 592.60M | 403.98M |
| Property, Plant & Equipment | 44.73M | 48.62M | 52.55M | 52.35M | 52.35M | 55.58M |
| Other Long-Term Assets | 4.85M | 4.64M | 2.90M | 1.70M | 1.64M | 1.64M |
| Total Assets | 373.94M | 332.39M | 551.33M | 487.72M | 646.59M | 461.19M |
| Accounts Payable | 5.96M | 6.67M | 12.46M | 2.58M | 5.36M | 3.73M |
| Accrued Expenses | 31.65M | 44.76M | 39.85M | 30.65M | 21.71M | 12.07M |
| Current Portion of Leases | 4.04M | 4.04M | 3.98M | 3.88M | 3.76M | 3.63M |
| Other Current Liabilities | 3.91M | 2.76M | 6.07M | 3.33M | 2.99M | 1.32M |
| Total Current Liabilities | 45.55M | 58.23M | 62.36M | 40.44M | 33.83M | 20.76M |
| Long-Term Debt | 99.77M | 83.31M | 46.38M | 44.81M | 28.65M | |
| Long-Term Leases | 23.39M | 24.24M | 25.80M | 27.18M | 28.35M | 29.21M |
| Other Long-Term Liabilities | 455.00K | 455.00K | 941.00K | 786.00K | 472.00K | |
| Total Liabilities | 169.16M | 166.23M | 135.49M | 113.21M | 91.30M | 49.96M |
| Common Stock | 95.00K | 82.00K | 77.00K | 61.00K | 57.00K | 47.00K |
| Additional Paid-In Capital | 1.59B | 1.42B | 1.36B | 1.07B | 1.03B | 723.36M |
| Retained Earnings | -1.39B | -1.26B | -948.58M | -701.28M | -485.49M | -311.20M |
| Comprehensive Income & Other | 5.92M | 5.40M | 5.45M | 4.86M | 5.73M | -973.00K |
| Total Common Equity | 204.78M | 166.16M | 415.84M | 374.51M | 555.29M | 411.23M |
| Shareholders' Equity | 204.78M | 166.16M | 415.84M | 374.51M | 555.29M | 411.23M |
| Total Liabilities & Equity | 373.94M | 332.39M | 551.33M | 487.72M | 646.59M | 461.19M |
| Total Debt | 127.19M | 111.59M | 76.17M | 75.87M | 60.76M | 32.84M |
| Net Cash (Debt) | 180.64M | 157.30M | 407.64M | 344.80M | 522.63M | 362.82M |
| Net Cash Per Share | 1.85 | 1.70 | 5.06 | 5.18 | 8.98 | 6.95 |
| Filing Date Shares Outstanding | 94.80M | 83.95M | 77.09M | 61.42M | 57.78M | 49.07M |
| Total Common Shares Outstanding | 94.81M | 82.72M | 77.09M | 61.42M | 56.68M | 47.34M |
| Working Capital | 278.48M | 220.89M | 433.52M | 393.23M | 558.78M | 383.22M |
| Book Value Per Share | 2.16 | 2.01 | 5.39 | 6.10 | 9.80 | 8.69 |
| Tangible Book Value | 204.78M | 166.16M | 415.84M | 374.51M | 555.29M | 411.23M |
| Tangible Book Value Per Share | 2.16 | 2.01 | 5.39 | 6.10 | 9.80 | 8.69 |
| Machinery | 17.14M | 16.66M | 14.89M | 13.86M | 12.23M | 10.32M |
| Construction In Progress | 139.00K | 802.00K | 1.65M | 1.12M | 783.00K | 1.62M |
| Leasehold Improvements | 2.50M | 2.50M | 2.50M | 1.89M | 1.71M | 785.00K |
Cash flow statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -271.03M | -313.94M | -247.30M | -215.79M | -174.28M | -118.04M |
| Depreciation & Amortization | 6.57M | 6.53M | 6.61M | 5.08M | 2.45M | 2.15M |
| Asset Writedown & Restructuring Costs | 830.00K | 188.00K | ||||
| Loss (Gain) From Sale of Investments | -350.00K | -2.54M | -8.95M | -12.33M | -5.64M | 2.22M |
| Stock-Based Compensation | 33.39M | 32.27M | 35.04M | 34.12M | 28.13M | 24.25M |
| Other Operating Activities | 1.29M | 991.00K | 1.37M | -2.04M | 6.17M | |
| Change in Accounts Payable | -469.00K | -4.94M | 9.94M | -2.79M | 1.98M | 1.12M |
| Change in Other Net Operating Assets | -5.90M | 1.10M | 11.03M | 8.28M | 13.14M | 6.12M |
| Operating Cash Flow | -245.55M | -280.34M | -192.25M | -185.47M | -128.05M | -82.18M |
| Capital Expenditures | -223.00K | -4.22M | -6.69M | -5.66M | -2.27M | -2.34M |
| Investment in Securities | 221.53M | 315.07M | -17.11M | 102.86M | -140.23M | 530.00K |
| Investing Cash Flow | 221.38M | 310.84M | -23.80M | 97.20M | -142.50M | -1.81M |
| Long-Term Debt Issued | 35.00M | 15.00M | 28.15M | |||
| Long-Term Debt Repaid | -736.00K | -599.00K | -476.00K | -365.00K | -264.00K | |
| Net Debt Issued (Repaid) | 49.19M | 34.26M | -599.00K | 14.52M | 27.79M | -264.00K |
| Issuance of Common Stock | 147.27M | 32.03M | 156.00M | 1.76M | 190.74M | 6.86M |
| Other Financing Activities | 31.02M | 97.00M | 92.78M | |||
| Financing Cash Flow | 227.48M | 66.29M | 252.40M | 16.28M | 311.30M | 6.60M |
| Foreign Exchange Rate Adjustments | 2.22M | 1.11M | 315.00K | -86.00K | -109.00K | 818.00K |
| Net Cash Flow | 205.53M | 97.91M | 36.66M | -72.07M | 40.64M | -76.57M |
| Free Cash Flow | -245.77M | -284.57M | -198.94M | -191.13M | -130.32M | -84.52M |
| Free Cash Flow Per Share | -2.52 | -3.07 | -2.47 | -2.87 | -2.24 | -1.62 |
| Levered Free Cash Flow | -148.30M | -172.25M | -109.63M | -113.44M | -71.10M | -44.13M |
| Unlevered Free Cash Flow | -141.44M | -166.71M | -104.70M | -109.28M | -68.50M | -42.74M |
| Cash Interest Paid | 6.12M | 4.69M | 4.20M | 3.04M | 1.07M | |
| Cash Income Tax Paid | 61.00K | -5.00K | 105.00K | 300.00K | 55.00K | |
| Change in Working Capital | -16.24M | -3.84M | 20.97M | 5.48M | 15.12M | 7.24M |
Ratios
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 1.85B | 631.68M | 750.89M | 501.54M | 1.00B | 801.56M |
| Enterprise Value | 1.67B | 438.89M | 290.40M | 111.00M | 444.55M | 414.49M |
| Last Close Price | 19.49 | 7.65 | 9.75 | 8.17 | 17.66 | 16.98 |
| PB Ratio | 9.02 | 3.80 | 1.81 | 1.34 | 1.80 | 1.95 |
| P/TBV Ratio | 9.02 | 3.80 | 1.81 | 1.34 | 1.80 | 1.95 |
| Debt / Equity Ratio | 0.62 | 0.67 | 0.18 | 0.20 | 0.11 | 0.08 |
| Net Debt / Equity Ratio | -0.88 | -0.95 | -0.98 | -0.92 | -0.94 | -0.88 |
| Net Debt / EBITDA Ratio | 0.69 | 0.50 | 1.60 | 1.51 | 3.04 | 3.21 |
| Net Debt / FCF Ratio | 0.73 | 0.55 | 2.05 | 1.80 | 4.01 | 4.29 |
| Quick Ratio | 6.76 | 4.65 | 7.82 | 10.53 | 17.33 | 19.31 |
| Current Ratio | 7.11 | 4.79 | 7.95 | 10.72 | 17.52 | 19.46 |
| Return on Equity (ROE) | -115.80% | -107.88% | -62.58% | -46.42% | -36.06% | -25.94% |
| Return on Assets (ROA) | -43.95% | -45.02% | -31.26% | -25.66% | -19.65% | -14.33% |
| Return on Capital Employed (ROCE) | -81.70% | -116.10% | -53.10% | -52.10% | -28.40% | -26.10% |
| Earnings Yield | -14.27% | -49.70% | -32.93% | -43.03% | -17.42% | -14.73% |
| FCF Yield | -13.30% | -45.05% | -26.49% | -38.11% | -13.03% | -10.54% |
| Buyback Yield / Dilution | -8.94% | -15.19% | -21.02% | -14.36% | -11.49% | -12.89% |